References
- Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492–1501.
- Ito K, Okamoto M, Ando M, et al. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma 2015;56:1123–1125.
- Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 2013;122:1946–1953.
- Witzens-Harig M, Foá R, Di Rocco A, et al. Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study. Ann Hematol 2014;93:1717–1724.
- Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entacavir prophylaxis for rituximab-associated Hepatitis B virus reactivation in patients with lymphoma and resolved Hepatitis B. J Clin Oncol 2013:31:2765–2772.
- DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012;482:405–409.
- Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400–404.
- García Muñoz R, Izquierdo-Gil A, Muñoz A, et al. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014;93:1879–1887.
- Lim SH, Pathapati S, Langevin J, et al. Severe CMV reactivation and gastritis during treatment of follicular lymphoma with bendamustine. Ann Hematol 2012;91:643–644.
- Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203–1210.
- Burchardt A, Barth J, Rummel MJ, et al. Immunochemotherapy with bendamustine-rituximab (BR) as induction therapy for indolent lymphomas results in a severe lymphopenia with low CD4 + amd CD8 + counts without an increase in atypical infections. First results of the infectious diesas (ID) project of a prospective, randomized, multicentre study (STIL NHL 7-2008; NCT00877214). Hematol Oncol 2013;31(Suppl. 1): Abstract 032.
- Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014;123:2944–2952.
- Misumi I, Whitmire JK. B cell depletion curtails CD4 + T cell memory and reduces protection against disseminating virus infection. J Immunol 2014;192:1597–1608.
- Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood 2014;123: 1957–1960.
- Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015;372:311–319.